Catalyst Pharmaceuticals, Inc.
CPRX
Rangering i aksjer
#4165
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Aksjekurs
$31.49
Sist synkronisert: 2026-07-21
Markedsverdi
$3.85B
Endring (1 dag)
0.00%
Endring (1 år)
49.88%
Land
US
Handel Catalyst Pharmaceuticals, Inc. (CPRX)
Kategori
Healthcare
P/S-forhold for Catalyst Pharmaceuticals, Inc. (CPRX)
P/S-forhold per October 2026 TTM: 6.46
Ifølge Catalyst Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 6.46. Ved slutten av 2023 hadde selskapet et P/S-forhold på 4.49.
P/S-historikk for Catalyst Pharmaceuticals, Inc. fra 2002 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.46 | 28.38% |
| 2024 | 5.03 | 12.06% |
| 2023 | 4.49 | -50.02% |
| 2022 | 8.98 | 80.63% |
| 2021 | 4.97 | 71.16% |
| 2020 | 2.90 | -23.05% |
| 2019 | 3.77 | -99.04% |
| 2018 | 394.11 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | 37.62 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | 55.20% |
US
|
|
| 40.55 | 527.95% |
US
|
|
| 3.96 | -38.66% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 57.12% |
NL
|
